Mehran Score Correlate With Rosuvastatin Attenuated Contrast Induced Nephropathy In Patients With Diabetes And Mild To Moderate Renal Dysfunction

Objective： Assessment Mehran score correlated with rosuvastatin attenuatedcontrast induced nephropathy in patients with diabetes and mild to moderate renaldysfunction. In order to reduce the occurrence of CIAKI, provide effectiveprevention methods.Methods: In this study,selected patients from December2008to September2010atthe General Hospital of Shenyang Military Region, coronary interventionalprocedures, select a sequence of400cases of diabetic patients with mild to moderaterenal insufficiency patients for statistical analysis.According to Mehran scoring riskstratification, observed the occurrence of CIAKI in400patients with diabetesmellitus and mild to moderate renal insufficiency after receiving medications afterreceiving medications in each risk stratification.The risk score of Mehran scoring system:Rated content, including: Systolicblood pressure <80mmHg (5points), Intra-aortic balloon pump (IABP)(5points),Congestive heart failure (5points), Anemia (3points), Diabetes (3points), Theamount of contrast agent (1/100ml), Serum creatinine>1.5mg/dL (4points),orglomerular filtration rate (2points, eGFR <60mL/min/1.73m2;4points,20mL/min/1.73m2<eGFR <40mL/min/1.73m2;6points, eGFR <20mL/min/1.73m2).Collection of finishing in patients with various risk factors, the ratingsrespectively integral and in accordance with the Mehran risk factors, and inaccordance with the total score will be divided into low, medium, high, veryhigh-risk group (low-risk0-5; risk:6-10points;:11-15high-risk; very high risk:≥16 points).The primary end-point was the occurrence of CIAKI, defined as an increase inserum creatinine≥0.5mg/dL (44.2μmol/L) or≥25%above baseline at72h afterexposure to contrast medium.Secondary endpoints:30-day composite end pointincluding NYHA class on admission to deteriorate more than one, hospitalized dueto deterioration of renal function, acute left ventricular failure, acute renal failure,all-cause mortality, requiring dialysis or hemofiltration, which haveone or more.Results: Mehran risk factors for the low-risk group (4/278,1.4%); risk group (3/113,2.7%),P=0.836; high-risk group and very high-risk group of patients less CIAKI.Mehran score in each group after30-day composite end point event rate r：low-riskgroup, risk group and high-risk2.5%,6.1%and22.2%.Conclusion:.With the the Mehran risk factors rated an increased risk of increase inthe incidence of contrast induced acute kidney injury,.30-day composite outcome ofrosuvastatin group and the control group in a higher incidence of high-risk group,rosuvastatin group than in the control group. In summary, The effective assessmentpatients perioperative the risk of CIAKI, appropriated to give the effectiveprevention and control measures can effectively reduce the occurrence of CIAKI.